Gastroparesis Treatment Market Research Report- Forecast to 2027

Gastroparesis Treatment Market Information, by Gastroparesis Type (Idiopathic, Diabetic, Post-surgical and Others), by Drug Class (Prokinetic drugs, Antiemetics, Antidepressants and Others) and by Other Treatment (Jejunostomy, Gastric electric stimulation (GES) and Parenteral Nutrition) - Forecast till 2027

ID: MRFR/Pharma/2322-HCR | February 2021 | Region: Global | 84 pages

Market Synopsis of Gastroparesis Treatment Market:

Market Scenario:

Gastroparesis is a condition of delayed gastric emptying because of partial paralysis of the stomach, resulting in food remaining in the stomach for an abnormally long time. The gastric muscles contracts to move food down into the small intestine which is controlled by the vagus nerve. Damage to the vagus nerve or the muscles of the stomach and intestines causes food to move slowly resulting in Gastroparesis. Gastroparesis predominantly affects young adult females. Although Gastroparesis is frequently associated with diabetes, idiopathic Gastroparesis accounts for the greatest number of cases.

The other market driving factors of Gastroparesis are surgery on the stomach or vagus nerve, anorexia nervosa, use of narcotics that slow gastric contractions, gastroesophageal reflux disease, disorders, such as amyloidosis and scleroderma, Parkinson's disease, metabolic disorders such as hypothyroidism, etc.

The Gastroparesis treatment market size is expected to reach around USD 5,323.62 million by the end of the forecast period and is expected to grow at a CAGR of ~ 3.8 %.

Study Objectives Gastroparesis Treatment Market:

  • To provide detail analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the global Gastroparesis Treatment market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, Porters Five Force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by Gastroparesis type, by drug class, by other treatment and other sub segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Global Gastroparesis Treatment Market Share, by Gastroparesis Type, 2016 (%):



Key Players for Global Gastroparesis Treatment Market:

  • Medtronic

  • Kimberly-Clark Corporation

  • Abbott Laboratories

  • Salix Pharmaceuticals, Inc

  • Boston Scientific Corporation

  • C. R. Bard, Inc

  • Janssen Global Services

  • LLC

  • Cardinal Health, Inc.

  • Alfa Wassermann SPA

  • Evoke Pharma

  • Rhythm Pharmaceuticals, Inc


Global Gastroparesis Treatment market has been segmented on the basis of Gastroparesis type which comprises idiopathic, diabetic, post-surgical and others. On the basis of drug class the market comprises of prokinetic drugs, antiemetics, antidepressants and others. On the basis of other treatment; market is segmented into jejunostomy, gastric electric stimulation (GES) and parenteral nutrition.

Regional Analysis of Global Gastroparesis Treatment Market:

Globally America is the largest market for Gastroparesis treatment. Europe is the second-largest market for Gastroparesis Treatment. Reasons for dominance of the developed regions is the faster market uptake, higher per capita income and excellent reimbursement scenario in these regions. Asia Pacific region is expected to be witness fastest growth and most of it will be led by Japan, China and India.

Intended Audience

  • Gastroparesis Treatment manufacturers

  • Gastroparesis Treatment suppliers

  • Private research laboratories

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Government research laboratories

The report for global Gastroparesis Treatment market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Report Scope:
Report Attribute/Metric Details
  Market Size   USD 5,323.62 million
  CAGR   2016-2023: ~ 3.8 %.
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Gastroparesis Type, Drug Class, Other Treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Medtronic, Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc., Boston Scientific Corporation, C. R. Bard, Inc., Janssen Global Services, LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, Rhythm Pharmaceuticals
  Key Market Opportunities

  • Higher Per Capita Income
  • Excellent Reimbursement Scenario in America Regions
  •   Key Market Drivers   Rising number of cases among adult females and use of drugs for slowing gastic contractions

    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Gastroparesis treatment market is expected to touch a value of USD 5,323.62 million by 2023.

    Gastroparesis treatment market can showcase a CAGR of 3.8% from 2017 to 2023.

    Gastroparesis treatment market is driven by the rising number of cases among adult females and use of drugs for slowing gastic contractions.

    Lack of awareness among farmers can hamper the growth of the global gastroparesis treatment market.

    Rhythm Pharmaceuticals, Inc., Janssen Global Services, Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc., LLC, Cardinal Health, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Kimberly-Clark Corporation, Medtronic, Evoke Pharma, and others are notable players of the global gastroparesis treatment market.

    1 Introduction

    1.1 Definition

    1.2 Scope of Study

    1.3 Research Objective

    1.4 Assumptions & Limitations

    1.5 Market Structure:

    2 Research Methodology

    2.1 Research Process

    2.2 Primary Research

    2.3 Secondary Research

    3 Market Dynamics

    3.1 Drivers

    3.2 Restraints

    3.3 Opportunities

    3.4 Challenges

    3.5 Macroeconomic Indicators

    4 Market Factor Analysis

    4.1 Porter’s five forces model

    4.1.1 Bargaining Power of suppliers

    4.1.2 Bargaining Power of Customer

    4.1.3 Intensity of Competitor’s

    4.1.4 Threat of New Entrants

    5 Global Gastroparesis Treatment Market, by Gastroparesis Type

    5.1 Introduction

    5.1.1 Idiopathic

    5.1.2 Diabetic

    5.1.3 Post-surgical

    5.1.4 Others

    6 Global Gastroparesis Treatment Market, by Drug Class

    6.1 Introduction

    6.1.1 Prokinetic drugs

    6.1.2 Antiemetics

    6.1.3 Antidepressants

    6.1.4 Others

    7 Global Gastroparesis Treatment Market, by Other Treatment

    7.1 Introduction

    7.1.1 Jejunostomy

    7.1.3 Gastric electric stimulation (GES)

    7.1.4 Parenteral Nutrition

    8 Global Gastroparesis Treatment Market, by Regions

    8.1 Introduction

    8.1.1 Americas North America South America

    8.1.2 Europe Germany France UK Italy Spain Rest of Europe

    8.1.3 Asia Pacific Japan China India Republic of Korea Rest of Asia Pacific

    8.1.4 Middle East & Africa

    9 Company Landscape

    9.1 Introduction

    9.1.1 Mergers Acquisitions

    9.1.2 Collaborations

    9.1.3 Release/New Product Launches

    9.1.4 Other (Expansion, Updates, Partnership)

    10 Company Profile

    10.1 Medtronic

    10.1.1 Company Overview

    10.1.2 Product/Business Segment Overview

    10.1.3 Financials

    10.1.4 Key Developments

    10.1.5 SWOT Analysis

    10.2 Kimberly-Clark Corporation

    10.2.1 Overview

    10.2.2 Product/Business Segment Overview

    10.2.3 Financials

    10.2.4 Key Developments

    10.2.5 SWOT Analysis

    10.3 Abbott Laboratories

    10.3.1 Overview

    10.3.2 Product/Business Segment Overview

    10.3.3 Financials

    10.3.4 Key Developments

    10.3.5 SWOT Analysis

    10.4 Salix Pharmaceuticals, Inc.

    10.4.1 Overview

    10.4.2 Product/Business Segment Overview

    10.4.3 Financials

    10.4.4 Key Developments

    10.4.5 SWOT Analysis

    10.5 Boston Scientific Corporation

    10.5.1 Overview

    10.5.2 Product/Business Segment Overview

    10.5.3 Financials

    10.5.4 Key Developments

    10.5.5 SWOT Analysis

    10.6 C. R. Bard, Inc.

    10.6.1 Overview

    10.6.2 Product/Business Segment Overview

    10.6.3 Financials

    10.6.4 Key Developments

    10.6.5 SWOT Analysis

    10.7 Rhythm Pharmaceuticals, Inc.

    10.7.1 Overview

    10.7.2 Product/Business Segment Overview

    10.7.3 Financials

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.8 Cardinal Health, Inc.

    10.8.1 Overview

    10.8.2 Product/Business Segment Overview

    10.8.3 Financials

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    10.9 Alfa Wassermann SPA

    10.9.1 Overview

    10.9.2 Product/Business Segment Overview

    10.9.3 Financials

    10.9.4 Key Developments

    10.9.5 SWOT Analysis

    10.10 Evoke Pharma

    10.10.1 Overview

    10.10.2 Product/Business Segment Overview

    10.10.3 Financials

    10.10.4 Key Developments

    10.10.5 SWOT Analysis

    10.11 Others

    11 Conclusion

    11.1 Key Findings

    11.1.1 From Ceo’s Viewpoint

    11.1.2 Unmet Needs of the Market

    11.2 Key Companies to Watch

    11.3 Prediction of Veterinary Surgical Instruments Industry

    12 Appendix